Research Analysts Set Expectations for TSE:BHC Q3 Earnings

Key Points

• Zacks Research raised its Q3 2025 earnings estimates for Bausch Health Companies to $1.51 per share, up from $1.46, indicating positive momentum in the company's earnings outlook.
• Bausch Health Companies' stock is currently trading at C$10.38, having a market cap of C$2.70 billion, and experiencing a slight decline of 0.5% on the day of the report.
• Corporate insiders, including Director John Paulson, have acquired significant shares amounting to over C$27 million in the last 90 days, suggesting increased confidence in the company's future prospects.

Bausch Health Companies Inc. (TSE:BHC - Free Report) - Equities research analysts at Zacks Research increased their Q3 2025 earnings per share (EPS) estimates for shares of Bausch Health Companies in a research note issued to investors on Wednesday, August 20th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.51 for the quarter, up from their prior forecast of $1.46. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q2 2026 earnings at $1.26 EPS and Q4 2026 earnings at $1.57 EPS.

Bausch Health Companies Stock Up 3.4%

Shares of Bausch Health Companies stock traded up C$0.33 on Monday, reaching C$10.16. 348,978 shares of the company were exchanged, compared to its average volume of 382,491. The stock's 50 day moving average price is C$9.24 and its 200-day moving average price is C$8.45. The company has a debt-to-equity ratio of -1,831.94, a current ratio of 1.19 and a quick ratio of 0.58. Bausch Health Companies has a 1-year low of C$5.91 and a 1-year high of C$13.74. The company has a market cap of C$3.76 billion, a P/E ratio of 39.08, a price-to-earnings-growth ratio of 0.21 and a beta of 0.11.

Insider Transactions at Bausch Health Companies

In other news, Director John Paulson purchased 1,782,030 shares of the stock in a transaction on Friday, June 13th. The stock was bought at an average price of C$8.14 per share, for a total transaction of C$14,501,803.73. Insiders have purchased a total of 3,553,401 shares of company stock valued at $27,087,675 in the last ninety days. 11.28% of the stock is owned by insiders.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.